What if a simple blood test could not only reveal the pace at which we age but also unveil the hidden risks of diseases looming on our horizon? Researchers at the Weizmann Institute of Science, led by Professors Liran Shlush and Amos Tanay, are pioneering studies that delve deep into the biology of blood to decode the enigmatic process of human aging and its intricate relationship with disease susceptibility. Their collaborative teams—comprising experts in medicine, biology, and computational data science—have unearthed pivotal insights centered on the dynamic behavior and genetic transformations occurring within blood-forming stem cells, particularly in individuals over the age of 40.
Central to these discoveries is the phenomenon whereby approximately one-third of aging adults harbor genetic alterations in their hematopoietic stem cells. These mutations do more than just incrementally raise the specter of blood malignancies such as leukemia; emerging evidence demonstrates their association with a broader spectrum of systemic diseases including cardiovascular ailments and metabolic disorders like diabetes. This interconnectedness suggests that the aging blood system acts as both a mirror and a predictor of overall health decline, positioning blood stem cells at the forefront of diagnostic innovation.
In a remarkable new publication unveiled in Nature Medicine, coinciding closely with the tragic missile strike that severely impacted their laboratories, Shlush and Tanay’s teams revealed groundbreaking advancements that could revolutionize the diagnosis of blood cancers. Their study introduces a novel, minimally invasive blood test designed to detect early indicators of leukemia risk, potentially supplanting the arduous and painful traditional method of bone marrow aspiration. This non-invasive approach leverages cutting-edge single-cell genetic sequencing to identify subtle aberrations in rare stem cells that circulate transiently in the bloodstream.
.adsslot_XmaSnydqC3{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_XmaSnydqC3{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_XmaSnydqC3{width:320px !important;height:50px !important;}
}
ADVERTISEMENT
The focal point of their research is myelodysplastic syndrome (MDS), a complex, age-related hematologic condition characterized by ineffective blood cell production due to faulty stem cell maturation. Diagnosing MDS has long required bone marrow biopsies, procedures demanding local anesthesia and often accompanied by discomfort and procedural risks. Accurate and timely diagnosis is vital because MDS can precipitate severe cytopenias, chronic anemia, and is prone to evolve into acute myeloid leukemia (AML), a highly aggressive blood cancer afflicting adults predominantly.
Breaking new ground, the research team, spearheaded by Dr. Nili Furer, Nimrod Rappoport, and Oren Milman, collaborated extensively with clinicians and scientists both in Israel and internationally. Their efforts illuminated that the rare cohort of stem cells escaping from the bone marrow into peripheral blood encapsulates rich diagnostic information. Exploiting sophisticated single-cell sequencing techniques, they demonstrated that analyzing these elusive cells via a simple blood draw can detect early molecular hallmarks of MDS with impressive resolution, enabling risk stratification for progression to leukemia.
Perhaps even more strikingly, the study uncovered that these circulating stem cells function as biological clocks reflective of an individual’s chronological and biological aging process. By cataloging shifts in their population dynamics, the researchers observed a sex-specific asymmetry: in males, notable alterations in stem cell characteristics occur earlier than in females, potentially elucidating the higher incidence and earlier onset of blood cancers among men. This insight opens compelling avenues for sex-tailored diagnostics and preventative interventions.
Beyond the implications for MDS and leukemia, the research holds vast promise for expanding to a spectrum of hematologic disorders. Profoundly, the team envisions a future where blood-based monitoring of stem cells informs personalized medicine approaches, detecting the onset of blood-related diseases before clinical symptoms manifest and enabling early therapeutic intervention. The current findings have already entered the stage of large-scale clinical trials at multiple medical centers worldwide, underscoring the translational impact of this research.
Professor Liran Shlush, beyond his research endeavors, maintains a vital clinical presence as a senior physician at Assuta Medical Center in Ashdod and within Maccabi Healthcare Services. His leadership extends into education as the head of the recently inaugurated Miriam and Aaron Gutwirth Medical School, an innovative program designed to harmonize medical training with frontline scientific research. This institution aims to cultivate the next generation of physician-scientists adept at bridging the divide between laboratory discoveries and bedside application.
The school’s unique curriculum intends to dissolve traditional boundaries between clinical practice and research, fostering a deeply integrated model that reflects the evolving landscape of modern medicine. Scheduled to commence its inaugural academic year this October, the program is poised to incubate talents capable of accelerating the adoption of breakthroughs such as the new blood test for MDS and leukemia risk, alongside myriad other biomedical innovations.
The research at the heart of these advances benefits from robust support by multiple prestigious institutions, foundations, and endowments. Among them are the Abisch-Frenkel RNA Therapeutics Center, the Sagol Institute for Longevity Research, and the EKARD Institute for Cancer Diagnosis Research, all of which facilitate the cutting-edge exploration into the molecular underpinnings of aging and cancer. Further backing by the Swiss Society Institute for Cancer Prevention Research and philanthropic contributions from the Laura and Anthony Beck family fund underscore the critical role of collaborative funding in propelling transformative science.
Similarly, Professor Amos Tanay’s investigations receive funding from the Adelis Foundation, as well as from several of the aforementioned cancer and longevity-focused research entities. This cross-disciplinary financial framework enables the sustained pursuit of innovative methodologies to decipher complex biological systems, utilizing advanced computational tools to parse vast datasets and extract meaningful biological insights.
This pioneering interconnected research exemplifies how the convergence of genetics, computational biology, and clinical medicine can chart new paths toward personalized healthcare pathways. The revelation that a circulating population of stem cells can chronicle age-related disease risk and serve as a minimally invasive diagnostic reservoir heralds a paradigm shift in hematology and beyond. As clinical validation continues through ongoing trials, the hope is that millions worldwide will soon benefit from improved, less invasive diagnostic options with profound implications for early detection and tailored treatment strategies.
The Weizmann Institute’s researchers have deftly transformed fundamental biological questions about aging into tangible medical advances, illustrating the power of integrative science and international collaboration. While their laboratories rebuild following the recent missile damage, the resilience and momentum of their scientific mission remain undeterred—ushering in a new era where a simple blood draw might unlock the secrets of aging and prevent devastating blood cancers before they take hold.
Subject of Research: Early detection and diagnostics of blood cancers and age-related hematologic disorders via single-cell genetic sequencing of blood stem cells.
Article Title: Novel Blood Test Unveils Aging Stem Cells’ Role in Predicting Leukemia and Age-Related Disease Risk
News Publication Date: 2025 (specific publication date: Friday, as per original article)
Web References:
Nature Medicine article
Prof. Liran Shlush’s lab
Prof. Amos Tanay’s lab
Miriam and Aaron Gutwirth Medical School
Keywords: Leukemia, Stem cells, Clinical medicine, Myelodysplastic syndrome, Aging, Single-cell sequencing, Blood cancer diagnostics, Hematopoietic stem cells, Personalized medicine
Tags: aging and health declineblood malignancies and systemic diseasesblood test for disease detectionbone marrow biopsies alternativesdiagnostic innovation in medicinegenetic alterations in aging adultshematopoietic stem cell mutationsleukemia risk assessmentpredictive biomarkers for chronic diseasesrelationship between aging and leukemiarole of blood tests in health monitoringWeizmann Institute of Science research
